Table 3 Active targeted NPs reported for osteosarcoma treatment
Type of nanocarrier | Targeting moiety | Drug | Performance | Reference |
|---|---|---|---|---|
Lipid-polymer NPs | CD133 apt | ATRA | In vitro: significant (p < 0.01) cytotoxicity towards Saos-2 CD133+ cells than apt-ATRA NPs and free ATRA. In vivo: substantially reduced tumor volume in BALB/c nude mice bearing osteosarcoma xenograft. | [63] |
Liposomes | HA | DOX | In vitro: significantly (p < 0.01) higher cytotoxicity towards MG63 cells than NRS and NHA liposomes. In vivo: efficient tumor suppression in MG63 xenograft mouse model than NRS and NHA liposomes. | [64] |
PMs | RGD | DOX | In vitro: remarkable cytotoxicity against MG-63 and MNNG/HOS OS cells than non-targeted DOX PMs. | [65] |
LC09-PPC-CRISPR/Cas9 NPs | LC09 aptamers | CRISPR/Cas9 plasmids encoding VEGFAgRNA and Cas9 | In vitro: enhanced cellular uptake than PPC-CRISPR/Cas9. In vivo: improved accumulation of LC09-PPC-CRISPR/Cas9 NPs in OS tissues and metastatic OS tissues in lung of the mice. | [66] |
BP nanoparticles | BP | DOX | In vivo: enhanced anti-tumor efficacy in mouse bearing Saos-2 human OS xenograft than free DOX. | [67] |
Polymeric NPs | CD133 apt | SAL | In vitro: increased cytotoxicity to Saos-2 CD133+ and U-2 OSCD133+ cells than SAL-NP and free SAL. | [68] |
LbL liposomes | Alendronate | DOX | In vivo: improved anti-tumor efficacy in nude mice bearing 143B xenografts. | [69] |